Q1 2025 saw revenue surge to KRW 27.0 billion and net income reach KRW 8.5 billion, driven by strong Bio-Chemical sales and improved margins. R&D remains a focus, with multiple late-stage clinical trials and new production facilities supporting future growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.